Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinoma

NCT06250036 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT06250036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06250036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinoma
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Suspended
Start date
February 20, 2025
Completion date
September 1, 2031
Enrollment
50 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric adenocarcinoma, msi-h/dmmr gastric cancer, msi-h/dmmr gastroesophageal-junction cancer